Samsung Bioepis Presents Phase 1 and 3 Clinical Results for
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced...
Source: globenewswire.com
Stay updated with breaking news from Reference Denosumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced...